secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001420720-25-000016
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio reports IBIO-600 NHP half-life up to 52 days; Activin E antibody shows 34% weight loss with semaglutide
--------------------------------------------------------------------------------

- IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.
- IBIO-600 promoted dose-dependent lean mass increase (3.1% low-dose, 5.1% high-dose) and fat reduction in NHPs after 8 weeks.
- Activin E antibody monotherapy in obese mice: 4% weight loss, 18% total body fat reduction vs placebo after 2 weeks.
- Activin E antibody combined with semaglutide: 34% total weight loss, 72% fat reduction – synergistic beyond GLP-1 alone.
- iBio on track for IBIO-600 regulatory submission in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/0001420720-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/ibio-20250407x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer